Trials / Conditions / Narcolepsy With Cataplexy

Narcolepsy With Cataplexy

15 registered clinical trials studyying Narcolepsy With Cataplexy — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Decreasing Nightmares in Adults With Narcolepsy NCT06383806	University of Utah	N/A
Recruiting	A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy NCT07363720	Takeda	Phase 3
Not Yet Recruiting	A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 NCT05914194	NLS Pharmaceutics	Phase 3
Completed	Narcolepsy Nightmare Study NCT05709873	Northwestern University	N/A
Completed	An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy NCT05055024	NLS Pharmaceutics	Phase 2
Completed	Awareness and Self-Compassion Enhancing Narcolepsy Treatment NCT04306952	Northwestern University	N/A
Suspended	'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' NCT04419792	University of Dublin, Trinity College	—
Completed	Clarithromycin Mechanisms in Hypersomnia Syndromes NCT04026958	Emory University	Phase 2
Completed	A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy NCT03030599	Jazz Pharmaceuticals	Phase 3
Completed	Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind St NCT02611687	Bioprojet	Phase 3
Completed	Xyrem and Brain Dopamine in Narcolepsy NCT02637076	Centre for Addiction and Mental Health	Phase 4
Completed	A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Saf NCT02221869	Jazz Pharmaceuticals	Phase 3
Completed	Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) NCT01800045	Bioprojet	Phase 3
Completed	Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes NCT00345800	UCB Pharma SA	Phase 1
No Longer Available	Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Dayt NCT03433131	Harmony Biosciences Management, Inc.	—